sorry thought it wuz going to Boeing Field and did not change muh description to match landing at Paine Field
Mebby planefag first with such a high profile AC-catching a cap of it on actual touchdown live.
Cannot recall seeing this ever.
This used as secondary AF2 and by State Dept.
>>64680 lb
SAM841 USAF C-40B on ground at Nellis AFB south from Hill AFB, SLC after a ground stop-inbound from JBA earlier today
>>64827
was not able to for a bit and muh id changed when I came back.
flood detect and hanging.
>muh static vpn malfunctioned
kek
Shockwave Medical, Inc sold by Sofinnova Partners: $66.60m-Mar 1
following on a $44.62m sale on Feb 22-linky below
ShockWave Medical, Inc. is a medical device company. The Company is focused on developing and commercializing products and establish care for medical device treatment of atherosclerotic cardiovascular disease. Its IVL System, which leverages IVL Technology, is a minimally invasive and improve patient outcomes. IVL System includes a generator, connector cable and a variety of IVL catheters designed to treat PAD and CAD. IVL Technology to crack calcium through short bursts of sonic pressure waves, which are generated within the IVL catheter, travel through the vessel and crack calcium with an effective pressure of up to 50 atmospheres (atm) (a unit of pressure) without harming the soft tissue.
https://www.marketscreener.com/quote/stock/SHOCKWAVE-MEDICAL-INC-55399621/company/
Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised ~$4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The two firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.
Sofinnova Partners is based in Paris, London, and Milan and focuses primarily on European biotech, medtech, biopharma, and industrial biotech investments, with a similar allocation for the US.
Sofinnova Ventures has offices in Menlo Park, CA, and San Diego, CA, and focuses largely on US biotech investments, with ~20% allocation for Europe.
Sofinnova Partners and Sofinnova Ventures have historically shared some of the same Limited Partners, and have co-invested together in various life sciences companies including Flamel, Cerep, Genset, Actelion, Preglem, Movetis, Ascendis, Obseva, Auris and Nucana. The firms have a collegial relationship and exchange information and due diligence. The firms do not have an obligation to disclose deals or to co-invest, but historically have co-invested together in ~10% of their collective investments.
https://en.wikipedia.org/wiki/Sofinnova
Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, ProQR, Shockwave Medical, NovusPharma (sold to CTI), Movetis (sold to Shire), Mainstay, Pixium Vision and Stentys, which went public respectively on the ZĂĽrich stock exchange, the NASDAQ, the Milan Nuovo Mercato, the Belgium Stock Exchange and the EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis), Ethical Oncology Science (EOS, sold to Clovis Oncology) and Recor Medical (sold to Otsuka). He has also invested in and is a board member of private companies Reflexion Medical, Tissium, Pi-Cardia, SafeHeal, Noema Therapeutics, Ablacare, Highlife and Rgenix.
https://www.sofinnovapartners.com/talents/antoine-papiernik
https://www.finviz.com/insidertrading.ashx?oc=1768408&tc=7&b=2
for the moment